Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
Feature|Articles|November 6, 2026
LITESPARK-012, XmAb819, and PE-PE Data Headline Key Kidney Cancer Findings From ESMO 2026
Author(s)Ryan Kret
Fact checked by: Chris Ryan
Advertisement
Advertisement
The addition of belzutifan (Welireg) or quavonlimab to pembrolizumab plus lenvatinib (Lenvima) in the phase 3 LITESPARK-012 trial (NCT04736706), the ENPP3 x CD3 bispecific antibody XmAb819 in the phase 1 XmAb819-01 trial (NCT05433142), and perioperative pembrolizumab plus metastasis-directed therapy in the phase 2 PE-PE trial (NCT05578664) were among the most closely watched kidney cancer data and themes presented at the
Related to this article
Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.
Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.
Durvalumab plus BCG is now an approved first-line option for high-risk NMIBC, but better BCG delivery and biomarker-guided selection should shape its use.
Lutetium Lu 177 vipivotide tetraxetan showed a median overall survival of 13.1 months in the French PSMA-REACH mCRPC cohort.
Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.
See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.
Community hematologists/oncologists discussed bispecific antibody integration in community practice for relapsed/refractory multiple myeloma.
Advertisement
Advertisement